Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-in Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for Er+ / Her2- Breast Cancer
atossa therapeutics完成了80mg藥代動力學試驗分組的招募，在第二期Evangeline臨床試驗中評估(Z)-Endoxifen作爲ER+/HER2-乳腺癌新輔助治療。